Elopag 25 mg (Eltrombopag) Tablets – Complete Guide to Uses, Dosage, Safety & Buying Options
Summary:
Low platelet counts create real daily risks. Easy bruising, nosebleeds, and the constant worry of more serious bleeding change how people live. Elopag 25 mg offers a clear path forward for many patients. This oral tablet contains Eltrombopag, a proven thrombopoietin receptor agonist that helps the bone marrow make more platelets.
Manufactured by Everest Pharmaceuticals PLC under cGMP standards and available through Unit Pharmacy (unitpharmacy.com), the 14-tablet pack supports patients across Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, Oman, Jordan, Lebanon, Syria, Yemen, Egypt, Turkey, Australia, and New Zealand.
What Is Elopag 25 mg and How Does It Work?
Elopag 25 mg is a film-coated tablet that delivers 25 mg of Eltrombopag (as Eltrombopag olamine). Everest Pharmaceuticals PLC produces it in Bangladesh under current Good Manufacturing Practice (cGMP) conditions. Each pack typically contains 14 tablets. The product is indicated for specific forms of thrombocytopenia and is not meant to normalize platelet counts completely.
Doctors use the lowest effective dose that reduces bleeding risk. Eltrombopag belongs to the thrombopoietin receptor agonist (TPO-RA) class. The body normally produces thrombopoietin to signal the bone marrow to make platelets.
Eltrombopag binds to a different site on the same receptor (the transmembrane domain). This binding starts the same signaling pathways that lead to more megakaryocytes and, ultimately, more circulating platelets. The effect is specific and dose-dependent. Patients usually see platelet counts begin to rise within the first one to two weeks. Full clinical benefit depends on the underlying condition and regular lab monitoring.
Product snapshot
| Feature | Detail |
| Manufacture | Everest Pharmaceuticals PLC. |
| Generic | Eltrombopag |
| Strength | 25 mg |
| Form | Film-coated tablet |
| Pack size | 14 tablets |
| Storage | Below 30 °C, protect from light |
| Prescription | Required |
Therapeutic Uses and Indications
Elopag 25 mg is approved for three main situations:
- Chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older who have not responded adequately to corticosteroids, immunoglobulins, or splenectomy. Doctors prescribe it only when the degree of thrombocytopenia raises the risk of bleeding.
- Thrombocytopenia associated with chronic hepatitis C in adults. Low platelets often prevent patients from starting or staying on interferon-based antiviral therapy. Raising the platelet count allows treatment to proceed.
- Severe aplastic anemia in adults and certain pediatric patients. It is used both as first-line therapy together with standard immunosuppressive treatment and in patients who have not responded well to prior immunosuppression and are not candidates for stem-cell transplant.
Important limitation: Elopag is not indicated for myelodysplastic syndromes. Safety and efficacy have not been established when combined with direct-acting antiviral agents used without interferon for hepatitis C.
Drug Class and Mechanism of Action of Elopag 25 mg
Eltrombopag is a small-molecule non-peptide thrombopoietin receptor agonist. Unlike the injectable pepti body romiplostim, which competes at the same binding site as natural thrombopoietin, Eltrombopag attaches to a distinct transmembrane region. This difference produces overlapping but not identical downstream signals (JAK-STAT, MAPK, and others).
The result is increased proliferation and differentiation of bone-marrow progenitor cells into platelet-producing megakaryocytes. Because the drug is oral and taken once daily, many patients find it more convenient than weekly injections. Food and polyvalent cations (calcium, iron, magnesium, aluminum, zinc) can reduce absorption, so timing rules are strict.
Dosage and Administration Guidelines of Elopag 25 mg
Dosing is highly individualized and based on platelet counts, age, ancestry, liver function, and the specific indication. Always follow the prescribing physician’s instructions. Typical starting regimens appear below.
Chronic ITP
- Adults and children ≥6 years (non-East Asian ancestry, normal liver function): 50 mg once daily.
- East/Southeast Asian ancestry or mild-to-severe hepatic impairment: 25 mg once daily.
- Combined East/Southeast Asian ancestry plus hepatic impairment: consider 12.5 mg once daily.
- Children 1–5 years: 25 mg once daily.
- Maximum dose: 75 mg per day.
- Goal: maintain platelet count ≥50 × 10⁹/L to reduce bleeding risk. Adjust in 25 mg steps every 2 weeks as needed.
Chronic hepatitis C–associated thrombocytopenia
- Start at 25 mg once daily for all patients.
- Increase by 25 mg every 2 weeks to reach the platelet level needed for antiviral therapy.
- Maximum dose: 100 mg per day.
- Stop when antiviral therapy ends.
Severe aplastic anemia
- First-line (with immunosuppressive therapy): age- and weight-based dosing (often higher starting doses such as 150 mg in adults ≥12 years; lower in younger children and Asian ancestry or hepatic impairment).
- Refractory: start at 50 mg once daily (25 mg in Asian ancestry or hepatic impairment); titrate up to a maximum of 150 mg daily. Response may take up to 16 weeks.
How to take the Elopag 25 mg tablet?
Swallow whole with water. Take on an empty stomach (at least 1 hour before or 2 hours after food). Separate from antacids, dairy products, and mineral supplements containing polyvalent cations by at least 2 hours before or 4 hours after. Do not crush or chew. Store below 30 °C (some labels specify below 25 °C), protected from light and moisture, and out of reach of children.
Clinical Evidence and Real-World Results
Multiple randomized trials support Eltrombopag across its indications. In chronic ITP, the RAISE study showed that patients on Eltrombopag spent a median of 11.3 weeks with platelet counts ≥50 × 10⁹/L versus 2.4 weeks on placebo. Response rates in earlier studies reached 59–81 % at various doses compared with 11–16 % on placebo.
Pediatric PETIT and PETIT2 trials confirmed meaningful response rates in children. For hepatitis C–associated thrombocytopenia, the ENABLE-1 and ENABLE-2 trials demonstrated that significantly more patients receiving Eltrombopag could start and maintain interferon-based therapy and achieve sustained virologic response.
In severe aplastic anemia, the RACE trial (NEJM 2022) found that adding Eltrombopag to standard immunosuppressive therapy improved complete response at 3 months (22 % vs 10 %) and overall response at 6 months (68 % vs 41 %).
Responses also occurred faster. Real-world data and long-term extensions show durable platelet responses in a substantial proportion of ITP patients with continued treatment, along with reduced need for rescue therapies and fewer bleeding events when counts are maintained.
Side Effects, Warnings, and Contraindications of Elopag 25 mg
Common side effects: (occurring in ≥20 % of patients in at least one indication) include anemia, nausea, fever (pyrexia), increased ALT, cough, fatigue, headache, and diarrhea. Many are mild to moderate and improve with time or dose adjustment.
Serious risks
- Hepatotoxicity: Monitor liver function tests before starting and regularly during treatment. Discontinue if criteria for drug-induced liver injury are met.
- Thrombotic/thromboembolic events: Portal vein thrombosis has been reported, especially in patients with chronic liver disease. Keep platelet counts from rising excessively.
- Progression of myelodysplastic syndromes to acute myeloid leukemia (when used off-label in MDS).
- Cataracts: Reported in some long-term users; eye examinations may be advised.
- Rebound thrombocytopenia after abrupt discontinuation.
Contraindications of Elopag 25 mg
Known hypersensitivity to Eltrombopag or any tablet component.
Special populations
Use caution in hepatic impairment (lower starting doses). Safety data in pregnancy are limited; breastfeeding is generally not recommended because of potential serious adverse reactions in the infant. Not established in children under 1 year for ITP or under certain ages for the other indications.
Comparative Safety Profile vs Alternatives
The main oral alternative in the TPO-RA class is Avatrombopag; the main injectable alternative is Romiplostim.
Feature | Eltrombopag | Romiplostim | Avatrombopag |
| Administration | Oral tablet, once daily | Weekly subcutaneous injection | Oral tablet, once daily |
| Food/cation restrictions | Strict empty-stomach rules | None | Fewer restrictions |
| Starting dose flexibility | Starting dose flexibility | Weight-based | Standard |
| Common monitoring | LFTs + platelets | Platelets | Platelets |
| Key differentiating risk | Liver enzyme elevations | Injection-site reactions, possible fibrosis concerns | Generally favorable liver profile |
| Efficacy in ITP | Strong, durable responses | Strong, durable responses | Strong responses |
Network meta-analyses and indirect comparisons generally find similar overall efficacy between Eltrombopag and romiplostim. Eltrombopag’s oral route and lower cost in many markets make it preferable for long-term outpatient use when liver function allows. Romiplostim may suit patients who cannot adhere to the empty-stomach rules or who prefer injection. Individual patient factors (liver status, preference, cost, prior response) guide the choice.
Drug Interactions and Monitoring Requirements
Polyvalent cations (antacids, iron, calcium, magnesium, zinc, selenium supplements, dairy) markedly reduce absorption. Space them as described above. Statins and certain other drugs may require dose adjustment because Eltrombopag is a mild inhibitor of some transporters and enzymes. Always provide a full medication list to the prescriber.
Required monitoring
- Complete blood count with differential and platelet count: weekly during titration, then monthly or as directed once stable.
- Liver function tests (ALT, AST, bilirubin): baseline, every 2 weeks during dose adjustment, then monthly.
- Continue platelet monitoring for at least 4 weeks after stopping therapy because of possible rebound.
- Ophthalmologic examination if long-term use is planned.
Patient Tips and When to Call a Doctor
Take the tablet at the same time each day to build a routine. Keep a simple log of doses and any bleeding or bruising. Avoid activities with high injury risk until platelet counts stabilize. Report new or worsening symptoms promptly.
Call your doctor or seek emergency care for:
- Unusual or prolonged bleeding, large bruises, blood in urine or stool, severe headache, or neurological changes (possible clotting).
- Yellowing of skin or eyes, dark urine, severe abdominal pain, or marked fatigue (possible liver issues).
- Signs of infection that do not resolve.
- Any sudden vision changes.
Do not stop the medicine suddenly without medical advice. Keep all scheduled lab appointments.
Pricing, Availability, and How to Order
Local prices vary. In Bangladesh, unit prices around ৳450 per tablet have been listed for 7- or 14-tablet packs, but international pricing depends on supplier, currency, and shipping.
Unit Pharmacy (unitpharmacy.com) supplies genuine
Everest Pharmaceuticals Elopag 25 mg in 14-tablet packs and ships via DHL Express or EMS to the listed target markets with tracked delivery typically in 5–20 days. A valid prescription is required. Prices are subject to change; confirm current cost and stock on the website or by contacting the pharmacy directly.
Insurance coverage and financial assistance programs differ by country. In some markets generic Eltrombopag is available and may reduce out-of-pocket expense. Always verify authenticity through licensed channels.
Patient Experiences and Practical Insights
Patients often report that once the correct dose is found, bruising and minor bleeding decrease and daily confidence improves. Some notice mild nausea or headache early on that settles with continued use or simple supportive measures.
The empty-stomach requirement can feel inconvenient at first; many solve it by taking the tablet first thing in the morning and waiting before breakfast or coffee with milk. Regular communication with the hematology team about lab results keeps treatment on track and prevents both under- and over-treatment.
Consideration: Keep in Mind
If you or a family member has been prescribed eltrombopag, or if your hematologist is considering a TPO-RA, review the full product information and discuss personal risks and benefits. For genuine Everest Pharmaceuticals Elopag 25 mg 14-tablet packs with tracked international shipping to the listed countries, visit Unit Pharmacy (unitpharmacy.com), upload a valid prescription, and complete your order. Prices and availability can change, so confirm current details directly.
Conclusion
Elopag 25 mg (eltrombopag) provides an effective oral option for patients whose low platelet counts put them at risk of bleeding. Clinical trials and real-world use confirm meaningful platelet responses across ITP, hepatitis C–associated thrombocytopenia, and severe aplastic anemia when dosing and monitoring are handled carefully. Side effects are generally manageable, and the oral route offers convenience for long-term therapy.
Frequently Asked Questions of Elopag 25 mg
- What is Elopag 25 mg used for?
Ans: It raises platelet counts in chronic ITP (after other treatments fail), in adults with hepatitis C–related thrombocytopenia so antiviral therapy can proceed, and in severe aplastic anemia (alone or with immunosuppression).
2.How long does it take for Elopag 25 mg to work?
Ans: Platelet counts often begin rising within 1–2 weeks. Full clinical benefit and dose optimization may take several weeks and require repeated blood tests.
3.Can I take Elopag 25 mg with food?
Ans: No. Take it on an empty stomach (1 hour before or 2 hours after food). Avoid dairy and mineral supplements for several hours around the dose because they reduce absorption.
- Is Elopag 25 mg the same as Promacta?
Ans: Elopag contains the same active ingredient (eltrombopag) as the originator brand Promacta. It is a generic version manufactured by Everest Pharmaceuticals. Bioequivalence is expected when manufactured to regulatory standards.
- What should I do if I miss a dose of Elopag 25 mg?
Ans: Skip the missed dose and take the next dose at the regular time. Do not double up. Contact your doctor if you miss several doses or are unsure.





Reviews
There are no reviews yet.